Effective connectivity changes in LSD-induced altered states of consciousness in humans
Psychedelics exert unique effects on human consciousness. The thalamic filter model
suggests that core effects of psychedelics may result from gating deficits, based on a …
suggests that core effects of psychedelics may result from gating deficits, based on a …
Drug management of hypertensive disorders of pregnancy
SM Khedun, J Moodley, T Naicker, B Maharaj - Pharmacology & …, 1997 - Elsevier
Drugs used in the acute and long-term management of hypertension in pregnancy and the
pre-eclampsia-eclampsia syndrome have been reviewed and their therapeutic effects and …
pre-eclampsia-eclampsia syndrome have been reviewed and their therapeutic effects and …
Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation
R Kraehenmann, D Pokorny, L Vollenweider… - …, 2017 - Springer
Rationale Accumulating evidence indicates that the mixed serotonin and dopamine receptor
agonist lysergic acid diethylamide (LSD) induces an altered state of consciousness that …
agonist lysergic acid diethylamide (LSD) induces an altered state of consciousness that …
Ketanserin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease
RN Brogden, EM Sorkin - Drugs, 1990 - Springer
Ketanserin is a 5-HT 2 receptor antagonist without partial agonist properties which also
possesses weak α 1-adrenoceptor antagonistic activity, which may explain its …
possesses weak α 1-adrenoceptor antagonistic activity, which may explain its …
Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers
Abstract The serotonin-2A receptor (5-HT 2A R) has been implicated in the pathogenesis of
schizophrenia and related inhibitory gating and behavioral inhibition deficits of …
schizophrenia and related inhibitory gating and behavioral inhibition deficits of …
Clinical pharmacokinetics of ketanserin
B Persson, J Heykants, T Hedner - Clinical pharmacokinetics, 1991 - Springer
Ketanserin is a serotonin S 2-receptor antagonist introduced for the treatment of arterial
hypertension and vasospastic disorders. Plasma concentrations of ketanserin (and some …
hypertension and vasospastic disorders. Plasma concentrations of ketanserin (and some …
Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension
T Hedner, B Persson - American Journal of Hypertension, 1988 - academic.oup.com
Ketanserin is an agent whose main pharmacologic action is antagonism of serotonin (5-
hydroxytryptamine, 5HT) receptors of the 5HT2 subtype. It also has weak α1-adrenergic …
hydroxytryptamine, 5HT) receptors of the 5HT2 subtype. It also has weak α1-adrenergic …
Serotonin antagonists fail to alter MDMA self-administration in rats
Abstract Acute exposure to±3, 4-methylenedioxymethamphetamine (MDMA) preferentially
increases release of serotonin (5-HT), and a role of 5-HT in many of the behavioral effects of …
increases release of serotonin (5-HT), and a role of 5-HT in many of the behavioral effects of …
Blockade of 5-HT2A receptors may mediate or modulate part of the immobility produced by inhaled anesthetics
Y Zhang, MJ Laster, EI Eger, CR Stabernack… - Anesthesia & …, 2003 - journals.lww.com
IMPLICATIONS: A subset of serotonin receptors, 5HT2A receptors, may mediate or modulate
a minor portion of the immobility produced by inhaled anesthetics. Results from studies from …
a minor portion of the immobility produced by inhaled anesthetics. Results from studies from …
Effects of cardiovascular disease on pharmacokinetics
V Rodighiero - Cardiovascular drugs and therapy, 1989 - Springer
The pathophysiologic changes occurring in cardiovascular disease can affect the kinetics of
drugs in several different ways. The present review examines these modifications and the …
drugs in several different ways. The present review examines these modifications and the …